<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">Colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) is one of the most common and preventable <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Regular consumption of apples is conducive to reduction in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> risk </plain></SENT>
<SENT sid="2" pm="."><plain>AIM OF THE STUDY: To evaluate effects of modified apple <z:chebi fb="5" ids="18154">polysaccharide</z:chebi> (MAP) on <z:mp ids='MP_0002006'>tumorigenesis</z:mp> in a mouse model of <z:hpo ids='HP_0002583'>colitis</z:hpo>-associated <z:hpo ids='HP_0003003'>colon cancer</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: One hundred male ICR mice were administered with 1, 2-dimethyl-<z:chebi fb="0" ids="15571">hydrazine</z:chebi> (DMH) and <z:chebi fb="0" ids="52071">dextran</z:chebi> <z:chebi fb="0" ids="32149">sodium sulfate</z:chebi> (DSS) </plain></SENT>
<SENT sid="4" pm="."><plain>Forty mice were given no further treatment, the rest were fed basal diet blended with three different doses of MAP; 2.5, 5, and 10% (20 mice in each group) </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: MAP significantly protected ICR mice against DMH/DSS-induced <z:mp ids='MP_0002006'>tumorigenesis</z:mp> </plain></SENT>
<SENT sid="6" pm="."><plain>The incidence of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> development was 90% (18/20) in the mice treated with DMH/DSS, but that was reduced to 25% (5/20), 15% (3/20), and 5% (1/20), respectively, in the mice treated with basal diets plus 2.5, 5, and 10% of MAP </plain></SENT>
<SENT sid="7" pm="."><plain>Study of <z:mpath ids='MPATH_3'>apoptosis</z:mpath> of colonic epithelial cells revealed that MAP moderately <z:mp ids='MP_0006042'>increased apoptosis</z:mp>, suggesting that the anti-<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> potency of MAP was probably attributed to its ability to induce <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="8" pm="."><plain>Western blot analysis demonstrated that carbohydrate-binding protein galectin-3 changed in both the nucleus and the cytoplasm during the process from <z:hpo ids='HP_0002583'>colitis</z:hpo> to <z:hpo ids='HP_0003003'>colon cancer</z:hpo> in the model </plain></SENT>
<SENT sid="9" pm="."><plain>And MAP could inhibit the binding of galectin-3 to its ligand: this is, at least in part, the possible mechanism of MAP by enhancing <z:mpath ids='MPATH_3'>apoptosis</z:mpath> and preventing <z:mp ids='MP_0002006'>tumorigenesis</z:mp> </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: These data suggest that MAP has a potential role in clinical prevention and treatment for <z:hpo ids='HP_0003003'>colon cancer</z:hpo> </plain></SENT>
</text></document>